Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis

Chinese Medical Journal

Volumn 126, Issue 5, 2013, Pages 850-854

  Guo, Ying Ying ^a   Wang, Nai Zhi ^a   Zhao, Shuai ^a   Hou, Lin Xin ^a   Xu, Yan Bing ^a   Zhang, Ning ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein; Interleukin 17; Interleukin 23; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; RHEUMATOID FACTOR;

ADULT; ARTICLE; BONE EROSION; CHRONIC ARTHRITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; X RAY ANALYSIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MIDDLE AGED;

EID: 84875302689     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20113093     Document Type: Article

References (28)

1. Clifton O, Bingham III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002; Suppl 65: 3-9.
2. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3541.
3. Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 2010; 71: 134-145.
4. Lupardus PJ, Garcia CK. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 2008; 382: 931-941.
5. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-1957.
6. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
7. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct. ll821976 CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
8. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
9. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483.
10. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by Il-17 through PI3-kinase-, NF-kappaB and p38 MAPK-dependent signalling pathways. Rheumatology 2007; 46: 57-64.
11. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682.
12. Zuo W, Wu ZH, Wu N, Duan YH, Wu JT, Wang H, Qiu GX. Adiponectin receptor 1 mediates the difference in adiponectin-induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts. Chin Med J 2011; 124: 3919-324.
13. Zhao S, Guo YY, Ding N, Yang LL, Zhang N. Changes in serum levels of soluble osteoclast-associated receptor in human rheumatoid arthritis. Chin Med J 2011; 124: 3058-3060.
14. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis-I: clinical features and diagnosis. BMJ 1995; 310: 587-590.
15. Miossec P. An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 218-222.
16. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
17. Trinchieri G, Wysocka M, D'Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, et al. Natural killer cell i. stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res 1992; 4: 355-368.
18. Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J. The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 2007; 55: 329-334.
19. Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008; 38: 2845-2854.
20. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008; 10: 206.
21. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222.
22. Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. Th-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008; 10: R93.
23. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-1352.
24. Steinman L. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
25. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro-and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009; 48: 602-606.
26. Koshy P, Henderson N, Logan C, Life P, Cawston T, Rowan A. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002; 61: 704-713.
27. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001; 3: 168-177.
28. Koenders MI, Lubberts E, Oppers-Walgreen B, Van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167: 141-149.